Home / Companies / Zevra Therapeutics, Inc. / 29 May 2025
Zevra Therapeutics, Inc.: meeting of 29 May 2025
Votes reported on Form N-PX, item by item
60 Form N-PX filers reported votes at the Zevra Therapeutics, Inc. meeting of 29 May 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
4 nominees; 81.3% of reported votes for; 11 filers withheld from or voted against at least one nominee.
433 vote records from 60 filers. 1 of the 60 filers that marked the item either way voted against management.
DIRECTOR ELECTIONSSecurity holder
Director elections (nominees put forward by security holders)
4 nominees; 0.0% of reported votes for; 49 filers withheld from or voted against at least one nominee.
346 vote records from 49 filers. 0 of the 49 filers that marked the item either way voted against management.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
196 vote records from 60 filers. 1 of the 60 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Directors | 3. Auditor |
|---|---|---|---|
| Vanguard | For | Abstain or withhold | For |
| BlackRock and iShares | Split or no vote | No report | For |
| Fidelity | For | Abstain or withhold | For |
| Dimensional | For | Abstain or withhold | For |
| State Street and SPDR | For | Abstain or withhold | For |
| Equitable | For | Abstain or withhold | For |
| Charles Schwab | For | Abstain or withhold | For |
| Nuveen and TIAA | For | Abstain or withhold | For |
| ProShares and ProFunds | For | Abstain or withhold | For |
| John Hancock and Manulife | Split or no vote | No report | For |
| Morgan Stanley, Eaton Vance and Calvert | For | Abstain or withhold | For |
| Goldman Sachs | For | Abstain or withhold | For |
| Northern Trust and FlexShares | For | Abstain or withhold | For |
| SEI | Split or no vote | No report | For |
| T. Rowe Price | For | Abstain or withhold | For |
| Lincoln Financial | Split or no vote | Split or no vote | Split or no vote |
| Voya | For | Abstain or withhold | For |
| Nationwide | For | Abstain or withhold | For |
| Victory Capital | For | Abstain or withhold | For |
| Brighthouse Funds | Split or no vote | Split or no vote | Split or no vote |
| Guggenheim and Rydex | For | Abstain or withhold | For |
| Columbia Threadneedle | For | Abstain or withhold | For |
| Pacific Life funds | For | Abstain or withhold | For |
| Global X | Split or no vote | No report | For |
| DWS | For | Abstain or withhold | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Zevra Therapeutics, Inc. meeting?
60 Form N-PX filers reported votes at the meeting of 29 May 2025. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Zevra Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Zevra Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Zevra Therapeutics, Inc. with a meeting date within three days of 29 May 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.